Richard Kent
Venture Partner, Intersouth Partners

Richard Kent, M.D. is a Venture Partner with Intersouth Partners, one of the nation's oldest early-stage venture capital firms, managing $780 million in seven venture capital partnerships.  Prior to joining Intersouth, Dr. Kent served as CEO of Serenex, Inc., a venture-backed biotechnology company acquired by Pfizer in April 2008. His prior positions include CEO of Ardent Pharmaceuticals, Senior Vice President, Global Medical Affairs, and Chief Medical Officer for GlaxoSmithKline, and other senior positions within Glaxo Wellcome and Burroughs Wellcome.

Dr. Kent has supervised dozens of INDs and more than 20 successful NDAs (and equivalent submissions in Europe and the rest of the world) in a wide range of therapeutic areas including CNS, Antivirals, HIV, Respiratory, Gastrointestinal, Anesthesia/Critical Care, Cardiovascular and Oncology.

Dr. Kent received his undergraduate degree from the University of California, Berkeley and his medical degree from the University of California, San Diego.  He completed his medical training at Harvard (Peter Bent Brigham Hospital), Stanford University Medical Center and Duke University Medical Center, and was a member of Duke University's medical faculty.  He is board certified in both internal medicine and cardiology.